Novelos Therapeutics: (OTC: NVLT)

$0.45

0.01 (2.27%)

Volume 54,682

May 23 02:57 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		0.44 - 0.45
	
		52wk Low - High
		0.36 - 2.01
	
		Previous Close
		0.44
	
		Avg. Volume
		33,348
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		25.25 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.61
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.21
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		NA
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		95 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of NA

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.21
                        
                            Current Quarter Estimate
                            -0.04
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            05-22-2013
                        
                            EPS Last Year
                            -0.29
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
NOVELOS THERAPEUTICS, INC. is a biopharmaceutical company commercializing oxidized glutathione based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy resistant ovarian cancer and early-stage breast cancer. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed.   
Full NVLT Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
NVLT Chart  by YCharts

Earnings Estimates

	Current Qtr (03/2013)	Next Qtr (06/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.04	-0.05	-0.21	-0.13
Number of Estimates	1	1	1	1
Low Estimate	-0.04	-0.05	-0.21	-0.13
High Estimate	-0.04	-0.05	-0.21	NA
Year Ago EPS	-0.06	NA	NA	-0.21
EPS Growth	33.33%	NA	NA	38.10%

More NVLT Estimates

Average Earnings Estimates for NVLT

EPS Growth for NVLT

Industry Analysis

Name	Symbol	Previous Close
NOVELOS THERAPT	NVLT	0.44
ANIKA THERAPEUT	ANIK	13.75
GENTIUM SPA-ADR	GENT	8.79
AASTROM BIOSCI	ASTM	0.57
ACADIA PHARMA	ACAD	13.42
ACHILLION PHARM	ACHN	7.74
ADDEX THERA LTD	ADDXF	6.62
AETERNA ZENTARS	AEZS	2.06
AFFYMAX INC	AFFY	1.40
ALEXION PHARMA	ALXN	100.57

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Current Decline in Share Price is an Opportunity to Accumulate Shares

Feb 14, 2013

Novelos Continues to Advance LIGHT Phase I/II Programs in Solid Tumors

Oct 26, 2012

Novelos Is Advancing Three Candidates Based On Its Unique Diapeutic Platform

Oct 08, 2012

NVLT - Development of CLR1502 (GLOW2) Further Expands Pipeline

Sep 10, 2012

Positive Initial Imaging Results From LIGHT Phase I/II Trial Observed

Jun 19, 2012

Report Not Available

More NVLT Zacks Commentary

Financials

EPS TTM	-0.29
Sales	0
Net Income	-10
Price/Earnings	NA
Price/Book	3.54
Price/Cash Flow	NA
Price/Sales	NA

More NVLT Financials

News

Novelos Therapeutics Provides Product Pipeline Update - Pr Newswire

May 16, 2013

Novelos Therapeutics Closes $5.5 Million Public Offering - Pr Newswire

Feb 21, 2013

Novelos Therapeutics Inc prices public offering of 11m units - M2

Feb 14, 2013

Novelos Therapeutics Prices $5.5 Million Public Offering - Eteligis

Feb 13, 2013

Novelos Therapeutics Prices $5.5 Million Public Offering - Pr Newswire

Feb 13, 2013

Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11 - Eteligis

Feb 4, 2013

Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11 - Pr Newswire

Feb 4, 2013

Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference - Eteligis

Jan 31, 2013

See All News Stories on NVLT

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	1
Average Target Price	2.35
Industry Rank by ABR	95 out of 265
Rank in Industry	4 out of 152

More NVLT Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member